Somaxon Pharmaceuticals (SOMX)
Somaxon Pharmaceuticals Revenue Growth: 18.04%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SOMX Revenue Growth Rankings
| Overall | 73rd percentile | 1155 of 4363 |
| Sector | 67th percentile | 148 of 457 in Healthcare |
| Industry | 56th percentile | 16 of 37 in Drug Manufacturers - Other |
SOMX Revenue Growth Range, Past 5 Years
| Minimum | 18.04% | Mar 2012 |
| Maximum | 9574% | Sep 2011 |
| Average | 3261% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these SOMX related companies
SOMX News
Somaxon Pharmaceuticals, Inc. (SOMX) Reports In-Line Q1 Loss of 4c/Share
May 10, 8:03AM Street Insider
May 10, 8:03AM Street Insider
Somaxon Pharmaceuticals to Report First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
Somaxon and CJ CheilJedang Announce Silenor® Collaboration in South Korea
Apr 27, 8:00AM Business Wire
Apr 27, 8:00AM Business Wire
$SOMX shares down ~7% after hours: P&G $PG didn't exercise option to develop, commercialize doxepin OTC product with Somaxon
about 59 days ago by Street_Insider
about 59 days ago by Street_Insider
Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street
Mar 08, 4:24PM Street Insider
Mar 08, 4:24PM Street Insider
Somaxon Reports Financial Results for Full Year and Fourth Quarter Ended December 31, 2011
Mar 08, 4:05PM Business Wire
Mar 08, 4:05PM Business Wire
I can't sleep war!!...now $SOMX downgraded PT $0.75, after $TSPT upgrade. Stock price alone speaks here
about 111 days ago by HighGrowthFinancial
about 111 days ago by HighGrowthFinancial
Somaxon Pharmaceuticals Hires Financial Advisor to Assist in Seeking Strategic Alternatives
Dec 19, 8:00AM Business Wire
Dec 19, 8:00AM Business Wire
Somaxon (SOMX), P&G (PG) to Evaluate Doxepin OTC Potential Through March 31st, 2012
Nov 25, 9:09AM Street Insider
Nov 25, 9:09AM Street Insider
Somaxon Pharmaceuticals, Inc. (SOMX) Reports Q3 Loss of $0.36,, Sales Fall Short
Nov 03, 8:21AM Street Insider
Nov 03, 8:21AM Street Insider
Somaxon Pharmaceuticals to Report Third Quarter 2011 Results and Conduct Conference Call on Thursday, November 3
Oct 19, 4:05PM Business Wire
Oct 19, 4:05PM Business Wire
$SOMX had large position that I sold over $10 with FDA approval, but held a handful....shares I held are down 88.82%. What a POS. lol
about 230 days ago by jestech27
about 230 days ago by jestech27
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SOMX | 0.30 | +0.01 | +3.45% | 13.95M |
| SOMH | 8.50 | +0.00 | +0.00% | 45.39M |
| SOL | 1.25 | -0.01 | -0.79% | 109.43M |
| SOHU | 43.21 | -1.56 | -3.48% | 1.705B |
| SOFO | 7.200 | -0.00 | -0.00% | 27.72M |
| SNSS | 2.92 | -0.09 | -2.99% | 140.93M |
| SNPS | 29.14 | -0.41 | -1.37% | 4.308B |
| SNP | 88.73 | -1.22 | -1.36% | 85.29B |
| SNN | 46.19 | -0.49 | -1.05% | 8.343B |
| SNMX | 2.23 | -0.08 | -3.46% | 91.87M |
